AI ASSISTANT
Ask DrugCentral
Explore drug information in your own words.
Type a question in the search bar above to get started. Each question is answered independently.
AI can make mistakes. Verify answers against the original sources before relying on them.
cefonicid 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | PK/Tox | Related Drugs | BioActivity |
| Stem definition | Drug id | CAS RN |
|---|---|---|
| antibiotics, cefalosporanic acid derivatives | 542 | 61270-58-4 |
Description:
| Molecule | Description |
|---|---|
|
Synonyms:
|
A second-generation cephalosporin administered intravenously or intramuscularly. Its bactericidal action results from inhibition of cell wall synthesis. It is used for urinary tract infections, lower respiratory tract infections, and soft tissue and bone infections.
Legend: OFP - off patent OFM - off market ONP - on patent |
Drug dosage:
| Dose | Unit | Route |
|---|---|---|
| 1 | g | P |
ADMET properties:
| Property | Value | Reference |
|---|---|---|
| BDDCS (Biopharmaceutical Drug Disposition Classification System) | 3 | Benet LZ, Broccatelli F, Oprea TI |
| EoM (Fraction excreted unchanged in urine) | 99 % | Benet LZ, Broccatelli F, Oprea TI |
| MRTD (Maximum Recommended Therapeutic Daily Dose) | 30.78 µM/kg/day | Contrera JF, Matthews EJ, Kruhlak NL, Benz RD |
| Vd (Volume of distribution) | 0.14 L/kg | Lombardo F, Berellini G, Obach RS |
| CL (Clearance) | 0.38 mL/min/kg | Lombardo F, Berellini G, Obach RS |
| fu (Fraction unbound in plasma) | 0.02 % | Lombardo F, Berellini G, Obach RS |
| t_half (Half-life) | 5.10 hours | Lombardo F, Berellini G, Obach RS |
| S (Water solubility) | 100 mg/mL | Bocci G, Oprea TI, Benet LZ |
Predicted pharmacokinetic/toxicological properties (PK-AZ):
| Property | Description | Value | Unit | Confidence | Similarity |
|---|---|---|---|---|---|
| azlogd74 | LogD at pH 7.4 | -2.633 | High | 0.80 | |
| caco2-efflux | Caco-2 efflux ratio (BA/AB) | 0.385 | High | 0.80 | |
| caco2-intrinsic-papp | Caco-2 intrinsic apparent permeability | 0.098 | 10^-6 cm/s | High | 0.80 |
| dh-clint | Dog hepatocyte intrinsic clearance | 1.426 | uL/min/10^6 cells | High | 0.80 |
| dppb | Dog plasma protein binding (% unbound) | 52.590 | % | High | 0.80 |
| fcs-ppb | Fetal calf serum protein binding (% unbound) | 53.050 | % | High | 0.80 |
| herg | hERG pIC50 | 4.613 | pIC50 | High | 0.80 |
| hh-clint | Human hepatocyte intrinsic clearance | 2.113 | uL/min/10^6 cells | High | 0.80 |
| hlm-clint | Human liver microsomal intrinsic clearance | 4.436 | uL/min/mg protein | High | 0.80 |
| hppb | Human plasma protein binding (% unbound) | 32.830 | % | High | 0.80 |
| kinase-safety-class | ACVR2A,ACVR2B,AURKA,AXL,BRAF,BTK,CAMK2D,CDK5,CDK9,DDR1,DYRK1B,EGFR,EIF2AK3,ERBB2,GRK2,GRK3,GSK3B,ITK,JAK2,JAK3,MAP2K6,MAP3K21,MAP3K7,MAPK10,MAPK7,MAPKAPK2,NTRK2,PDK1,PDK2,PIK3CB,PIM2,PRKDC,SIK2,STK33,SYK,TEK,TTK,ZAP70 | 38 | |||
| kinase-selectivity-class | AXL,BRAF,CDK9,DYRK1B,EIF2AK3,EPHB4,ERBB2,GRK2,JAK2,MAP2K6,MAPK7,PRKDC,STK33,TEK,TGFBR1 | 15 | |||
| mdck-mdr1-efflux | MDCK-MDR1 efflux ratio | 0.151 | High | 0.80 | |
| mh-clint | Mouse hepatocyte intrinsic clearance | 3.266 | High | 0.80 | |
| mppb | Mouse plasma protein binding (% unbound) | 49.370 | High | 0.80 | |
| nih-mdck-mdr1-efflux | NIH MDCK-MDR1 efflux ratio | 0.186 | High | 0.80 | |
| pfas-class | PFAS structural alert (1 = True, 0 = False) | 0 | |||
| pppb | Pig plasma protein binding (% unbound) | 30.190 | % | High | 0.80 |
| rh-clint | Rat hepatocyte intrinsic clearance | 1.327 | uL/min/10^6 cells | High | 0.80 |
| rh-fuinc | Rat hepatocyte fraction unbound in incubation | 85.740 | % | High | 0.80 |
| rppb | Rat plasma protein binding (% unbound) | 20.900 | % | High | 0.80 |
| solubility-dd | Solubility at pH 7.4 in DMSO | 926.830 | uM | High | 0.80 |
Approvals:
| Date | Agency | Company | Orphan |
|---|---|---|---|
| None | FDA | GLAXOSMITHKLINE |
FDA Adverse Event Reporting System (Female)
None
FDA Adverse Event Reporting System (Male)
None
FDA Adverse Event Reporting System (Geriatric)
None
FDA Adverse Event Reporting System (Pediatric)
None
Pharmacologic Action:
| Source | Code | Description |
|---|---|---|
| ATC | J01DC06 | ANTIINFECTIVES FOR SYSTEMIC USE ANTIBACTERIALS FOR SYSTEMIC USE OTHER BETA-LACTAM ANTIBACTERIALS Second-generation cephalosporins |
| CHEBI has role | CHEBI:33282 | antibacterial agent |
| CHEBI has role | CHEBI:36047 | antibacterial drug |
| MeSH PA | D000890 | Anti-Infective Agents |
| MeSH PA | D000900 | Anti-Bacterial Agents |
Related Drugs by ATC class:
J01DC Second-generation cephalosporins 13 drugs
Drug Use | Suggest Off label Use Form| |View source of the data|
| Disease | Relation | SNOMED_ID | DOID |
|---|---|---|---|
| Septicemia due to Escherichia coli | indication | 9323009 | |
| Bacterial septicemia | indication | 10001005 | DOID:0040085 |
| Infection of skin AND/OR subcutaneous tissue | indication | 19824006 | |
| Streptococcal septicemia | indication | 29577008 | |
| Pneumonia due to Streptococcus | indication | 34020007 | |
| Lower respiratory tract infection | indication | 50417007 | |
| Pneumonia due to Escherichia coli | indication | 51530003 | |
| Klebsiella cystitis | indication | 60867007 | |
| Urinary tract infectious disease | indication | 68566005 | |
| Haemophilus influenzae pneumonia | indication | 70036007 | |
| Infection of bone | indication | 111253001 | |
| Bacterial infection due to Klebsiella pneumoniae | indication | 186435004 | |
| Pneumonia | indication | 233604007 | DOID:552 |
| Escherichia coli urinary tract infection | indication | 301011002 | |
| Proteus urinary tract infection | indication | 301012009 | |
| Streptococcus pyogenes infection | indication | 302809008 | |
| Infectious disorder of joint | indication | 363162000 | |
| Infection due to Staphylococcus aureus | indication | 406602003 | |
| Osteomyelitis due to Staphylococcus aureus | indication | 428783003 | |
| Skin and Skin Structure Streptococcus Agalactiae Infection | indication | ||
| Morganella Morganii Urinary Tract Infection | indication | ||
| Staphylococcus Epidermidis Skin and Skin Structure Infection | indication | ||
| Prosthetic Arthroplasty Infection Prevention | indication | ||
| Providencia Urinary Tract Infection | indication | ||
| Prevention of Perioperative Infection | indication |
🐶 Veterinary Drug Use
None
🐶 Veterinary products
None
Acid dissociation constants calculated using MoKa v3.0.0
| Dissociation level | Dissociation constant | Type (acidic/basic) |
|---|---|---|
| pKa1 | 2.63 | acidic |
| pKa2 | 11.72 | acidic |
Orange Book patent data (new drug applications)
None
Orange Book exclusivity data (new drug applications)
None
Bioactivity Summary:
| Target | Class | Pharos | UniProt | Action | Type | Activity value (-log[M]) | Mechanism action | Bioact source | MoA source |
|---|---|---|---|---|---|---|---|---|---|
| Somatostatin receptor type 4 | GPCR | IC50 | 4.24 | WOMBAT-PK | |||||
| Matrix metalloproteinase-9 | Enzyme | IC50 | 5.04 | WOMBAT-PK | |||||
| Prostaglandin G/H synthase 2 | Enzyme | IC50 | 4.48 | WOMBAT-PK | |||||
| Bacterial penicillin-binding protein | Enzyme | INHIBITOR | CHEMBL | CHEMBL | |||||
| Penicillin-binding protein 1A | Enzyme | WOMBAT-PK |
External reference:
| ID | Source |
|---|---|
| 4019661 | VUID |
| N0000147753 | NUI |
| D00912 | KEGG_DRUG |
| 2183 | RXNORM |
| C0007551 | UMLSCUI |
| CHEBI:3491 | CHEBI |
| CHEMBL1601 | ChEMBL_ID |
| CHEMBL1201005 | ChEMBL_ID |
| D015790 | MESH_DESCRIPTOR_UI |
| DB01328 | DRUGBANK_ID |
| 12217 | IUPHAR_LIGAND_ID |
| 4479 | INN_ID |
| 61270-78-8 | SECONDARY_CAS_RN |
| 6532B86WFG | UNII |
| 43594 | PUBCHEM_CID |
| 1008 | MMSL |
| 1887 | MMSL |
| 4376 | MMSL |
| d00063 | MMSL |
| 35343004 | SNOMEDCT_US |
| 370353006 | SNOMEDCT_US |
| 58343005 | SNOMEDCT_US |
| 4018011 | VANDF |
| 4019661 | VANDF |
| 002732 | NDDF |
| 004848 | NDDF |
Pharmaceutical products:
None